Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up

J Neurol. 2021 Aug;268(8):2700-2702. doi: 10.1007/s00415-020-10310-x. Epub 2020 Nov 20.

Affiliations

¹ Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. julia.wanschitz@i-med.ac.at.
² Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
³ Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
⁴ Department of Radiology II, Medical University of Innsbruck, Innsbruck, Austria.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Follow-Up Studies
Humans
Myasthenia Gravis* / complications
Myasthenia Gravis* / drug therapy
Rituximab / adverse effects
SARS-CoV-2

Substances

Rituximab